|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0382781B1
(en)
|
1987-10-23 |
1993-09-29 |
Genetics Institute, Inc. |
Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
WO1993025687A1
(en)
|
1992-06-09 |
1993-12-23 |
Chiron Corporation |
Crystallization of m-csf
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999029345A1
(en)
|
1997-12-05 |
1999-06-17 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
CA2348292A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparation
|
|
ATE240744T1
(de)
|
1999-10-28 |
2003-06-15 |
Hofbauer Reinhold |
Verwendung von csf-1-inhibitoren
|
|
WO2001034177A2
(en)
|
1999-11-08 |
2001-05-17 |
The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
EP1572106B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
US7807389B2
(en)
|
2003-03-14 |
2010-10-05 |
University Of Rochester |
Methods and compositions related to joint inflammation diseases
|
|
CN101979650B
(zh)
|
2003-10-22 |
2015-09-16 |
凯克研究生院 |
使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
WO2005070447A2
(en)
|
2004-01-21 |
2005-08-04 |
Chiron Corporation |
M-csf muteins and uses thereof
|
|
CA2565974A1
(en)
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
ATE540973T1
(de)
|
2004-07-22 |
2012-01-15 |
Five Prime Therapeutics Inc |
Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
CA2589895A1
(en)
|
2005-01-27 |
2006-08-03 |
Five Prime Therapeutics, Inc. |
Leader sequences for directing secretion of polypeptides and methods for production thereof
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
KR20080082628A
(ko)
|
2005-11-10 |
2008-09-11 |
리셉터 바이오로직스 인크 |
수용체 및 리간드 이소형태의 제조 방법
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
EP1977238B1
(en)
|
2005-12-22 |
2016-09-28 |
Novartis AG |
Soluble human m-csf receptor and uses thereof
|
|
JP5580535B2
(ja)
|
2006-01-05 |
2014-08-27 |
ノバルティス アーゲー |
癌転移および癌転移に関連する骨量減少を予防および処置するための方法
|
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
|
US20100036091A1
(en)
|
2006-11-10 |
2010-02-11 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
CA2669599A1
(en)
|
2006-11-17 |
2008-05-22 |
Biogen Idec Ma Inc. |
Systemic administration of colony stimulating factors to treat amyloid associated disorders
|
|
DE602008004296D1
(de)
|
2007-02-14 |
2011-02-17 |
Vaccinex Inc |
Humanisierte anti-cd100-antikörper
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
ES2452349T3
(es)
|
2007-05-21 |
2014-04-01 |
Novartis Ag |
Inhibidores de CSF-1R, composiciones, y métodos de uso
|
|
US20100298217A1
(en)
|
2007-05-30 |
2010-11-25 |
Evan Richard Stanley |
Csf-1r mutants
|
|
MX2010001918A
(es)
|
2007-08-21 |
2010-03-11 |
Amgen Inc |
Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
EA201000620A1
(ru)
|
2007-10-18 |
2010-12-30 |
Новартис Аг |
Ингибиторы csf-1r, предназначенные для лечения рака и заболеваний костей
|
|
AU2008318656A1
(en)
|
2007-10-31 |
2009-05-07 |
Janssen Pharmaceutica N.V. |
Biomarker for assessing response to FMS treatment
|
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
|
CN101970496B
(zh)
|
2008-03-14 |
2014-04-16 |
特朗斯吉有限公司 |
针对csf-1r的抗体
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
AU2009257635A1
(en)
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
|
|
US8080246B2
(en)
|
2008-11-26 |
2011-12-20 |
Five Prime Therapeutics, Inc. |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
|
|
WO2010062401A2
(en)
|
2008-11-26 |
2010-06-03 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
|
|
UA105813C2
(uk)
|
2009-11-06 |
2014-06-25 |
Плексікон, Інк. |
Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
|
|
AU2010329934B2
(en)
|
2009-12-10 |
2015-05-14 |
F. Hoffmann-La Roche Ag |
Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
|
|
PT2516433E
(pt)
|
2009-12-21 |
2014-09-03 |
Array Biopharma Inc |
Compostos de n-(1h-indazol-4-il)imidazo[1,2- a]piridina-3 carboxamida substituída como inibidores de cfms
|
|
MX2012010014A
(es)
|
2010-03-05 |
2012-09-21 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
CA2789071C
(en)
*
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
MX355418B
(es)
|
2010-05-04 |
2018-04-18 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
AR084234A1
(es)
|
2010-12-13 |
2013-05-02 |
Novartis Ag |
Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
|
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
|
HK1200032A1
(en)
|
2011-10-21 |
2015-07-31 |
Transgene Sa |
Modulation of macrophage activation
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
CN106267210A
(zh)
*
|
2012-03-26 |
2017-01-04 |
日本化学药品株式会社 |
骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂
|
|
JP2015517490A
(ja)
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
US20130302322A1
(en)
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|